Personalising pancreas cancer treatment:When tissue is the issue

作     者：Katrin M Sjoquist Venessa T Chin Lorraine A Chantrill Chelsie O'Connor Chris Hemmings David K Chang Angela Chou Marina Pajic Amber L Johns Adnan M Nagrial Andrew V Biankin Desmond Yip 

作者机构：NHMRC Clinical Trials CentreUniversity of SydneySydney NSW 1450Australia Cancer Care CentreSt George HospitalKogarah NSW 2217Australia The Kinghorn Cancer Centreand the Cancer Research ProgramGarvan Institute of Medical ResearchSydney NSW 2010Australia Macarthur Cancer Therapy CentreCampbelltown HospitalCampbelltown NSW 2560Australia St Vincents Hospital Clinical SchoolSydney UNSW 2010Australia Cancer Therapy CentreLiverpool HospitalLiverpool NSW 2170Australia St John of God PathologySubiaco WA 6904Australia Department of SurgeryBankstown HospitalEldridge RoadBankstownSydney NSW 2200Australia Faculty of MedicineSouth Western Sydney Clinical SchoolUniversity of NSWLiverpool NSW 2170Australia Wolfson Wohl Cancer Research CentreInstitute of Cancer SciencesUniversity of GlasgowGlasgow G61 1BDUnited Kingdom Department of Anatomical PathologySt.Vincent’s HospitalDarlinghurstSydney NSW 2010Australia West of Scotland Pancreatic UnitGlasgow Royal InfirmaryGlasgow G4 0SFUnited Kingdom Department of Medical OncologyThe Canberra HospitalGarran ACT 2605Australia ANU Medical SchoolAustralian National UniversityActon ACT 2601Australia 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2014年第20卷第24期

页      面：7849-7863页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：Supported by NHMRC,Pancare Australia,Sydney Catalyst,Royal Australasian College of Physicians to Chin VT NHMRC Programme Grant to Sjoquist KM 

主　　题：Pancreatic neoplasms Molecular targeted therapy Genomics Tissue banks Chemotherapy 

摘      要：The treatment of advanced pancreatic cancer has not moved much beyond single agent gemcitabine until recently when protocols such as FOLFIRINOX(fluorouracil,leucovorin,irinotecan and oxaliplatin)and nab-paclitaxelgemcitabine have demonstrated some improved *** in technology especially in massively parallel genome sequencing has progressed our understanding of the biology of pancreatic cancer especially the candidate signalling pathways that are involved in tumourogenesis and disease *** has allowed identification of potentially actionable mutations that may be targeted by new biological *** heterogeneity of pancreatic cancer makes tumour tissue collection important with the aim of being able to personalise therapies for the individual as opposed to a one size fits all approach to treatment of the *** paper reviews the developments in this area of translational research and the ongoing clinical studies that will attempt to move this into the everyday oncology practice.